Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1.

ABSTRACT:

Background

The effectiveness of specific regimens of adjuvant therapy for gastric cancer has not been verified by large clinical trials. Recently, several large trials attempted to verify the effectiveness of adjuvant therapy. The Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer in Japan, a randomized controlled trial of adjuvant S-1 therapy for resected gastric cancer, demonstrated significant improvement in overall and relapse-free survival, compared to surgery alone. To evaluate value for money of S-1 therapy, cost-effective analysis was carried out.

Methods

The analysis was carried out from a payer's perspective. As an economic measure, cost per quality-adjusted life-year (QALY) gained was estimated. Overall survival was estimated by the Kaplan-Meier method, up to

SUBMITTER: Hisashige A 

PROVIDER: S-EPMC3816158 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature